



Integrated APIs & FDFs:
Science. Scale. Speed.

Cohance at a Glance

35+

Years of Experience

15+

Innovator Relationships

15+

Years Average Partnership

1,000+

CDMO Projects Executed

18

CDMO Commercial Molecules

200+

DMFs filed globally across 50+ molecules

3 billion+

OSD manufacturing capacity annually

7

R&D Centres

500+

Scientists

13


Manufacturing Sites

8

USFDA / EDQM Accredited Sites

3500+KL

Reactor Capacity



Achieved B rating in Climate Change and A- Water in 2025



Gold in EcoVadis Sustainability Assessment Jan 2026



Targets have been approved by SBTI



97% score in TFS audit



Pharmaceutical Supply Chain Initiative (PSCI) Supplier Partner-2025



UN Global Compact Commitment for SDG Implementation



UN Global Women Empowerment Program (WEP)



Global Safety Accolade



All facilities are certified with ISO 14001, ISO 45001, ISO 37001, ISO 27001, ISO 20400, ISO 50001, ISO 22307, ISO 9001.



Installation of 7 MWp solar power plant under Group Captive (GC) model is completed for Ankleswar site.

Our ESG Goals & Aspirations towards shaping a sustainable future

58+%

Reduction in Scope 1, 2 and 3 emissions from current level by 2035

35+%

Reduce absolute Scope 3 emissions from current level by 2035

30%

Reduce, reuse and recycle specific water consumption by 2030

90+%

Transition to renewable energy sources of total energy use and reduce absolute Scope 1,2 and 3 emissions from current level by 2050

15%

Reduction in hazardous waste going to landfill by 2030

20%

Women representation in workforce by 2030

Net Zero

GHG emissions by 2050



Integrated Generic API Platform offering solutions across pharma value chain

Cohance's Generic APIs platform offers an integrated approach to serve global customers across high-growth therapeutic areas. Built on a legacy of deep chemistry expertise, we support partners in 60+ countries with reliable, end-to-end solutions.

Why Cohance for Generic APIs

Diverse Portfolio

200+ DMFs filed globally across 50+ molecules

Scale & Reliability

1600+ KL operational capacity across 5 cGMP facilities

Regulatory Strength

15+ successful global regulatory audits in last 2 years

Multi-step Backward Integration

Reliable API supplies enabled by backward integration.

Chemistry at Core

3 R&D centers, 150+ scientists dedicated to generics innovation, handling complex and non-infringing chemistry

Lifecycle Management

Integrated platform capabilities for innovator lifecycle support

Controlled Substances Expertise

Uniquely curated intermediates and APIs portfolio

Integrated FDF Platform

Our FDF division delivers end-to-end solutions — from development to commercialization — helping customers accelerate access to quality medicines worldwide.

Why Cohance for FDFs

Scale & Reliability

3 state-of-the-art facilities, flexible from pilot to commercial scale

Diverse Dosage Coverage

Oral solids, modified release, liquids, semisolids, sachets, topical cloths

R&D Depth

70+ formulation scientists, 40+ commercialized products

Integrated Approach

APIs + FDFs under one roof for faster time-to-market

Global Reach

30+ markets including US, EU, LatAm, Asia, Africa

Regulatory Confidence

USFDA, EU-GMP, WHO-GMP, ANVISA, PMDA, TGA, Health Canada





Global-Accredited Infrastructure



APIs

- 5 cGMP plants | 1600+ KL reactor capacity
- Backward integration for sustainable supply
- 2 R&D centers with 150+ scientists
- **Global accreditations:** USFDA, EDQM, PMDA, ANVISA, Health Canada, TGA
- Delivering complex chemistry with precision, scale & speed

FDFs

- 3 cGMP facilities + 1 dedicated R&D center
- **Capacity Highlights**
 - **Tablets:** 3 Billion+ units annually
 - **Capsules:** 150M+ units
 - **Liquids:** 170 KL
 - **Semisolids & Topicals:** 15 MT
 - **Topical cloths:** 20M units
- **Global approvals:** USFDA, EU-GMP, WHO-GMP, TGA, Health Canada

Generic API+

API Unit-I, Jaggayapet ●
Andhra Pradesh, India

API Unit-II, Atchutapuram ●
Andhra Pradesh, India

API Unit-III, Ankaleshwar ●
Gujarat, India

API R&D Unit-I, Genome Valley ●
Telangana, India

API R&D Unit-II, Ankaleshwar ●
Gujarat, India

FDF Unit-I, Nacharam ●
Telangana, India

FDF Unit-II, Jadcherla ●
Telangana, India

FDF Unit-III, Pashamylaram ●
Telangana, India

FDF Unit-IV, Shamshabad ●
Telangana, India

FDF R&D, Nacharam ●
Telangana, India

● R&D/Early-Stage Manufacturing

● Late-Stage/Commercial Manufacturing

Active Pharma Ingredients - Commercial

Product	USDMF	CEP	EDMF	C-DMF	CA-DIF	KDMF	RUSSIA	ANVISA BRAZIL	Therapeutic Use
Aripiprazole	√	√		√		√			Antipsychotic, Antidepressant
Articaine HCl		√				√	√		Anesthetic
Atomoxetine HCl	√	√		√	√		√	**	ADHD
Baclofen	*	√	√	*		√	√		Skeletal Muscle Relaxant
Benserazide		√				√			Anti-Parkinson
Betahistine DiHCl		√		√	√	*	√	*	Anti-Vertigo
Buspirone	√	√							Anti-anxiety
Calcium Acetate	√								Phosphate-removing Agent
Cilostazol	*								Antiplatelet
Dabigatran Etexilate Mesylate		*							Anticoagulant
Dapagliflozin Propanediol Monohydrate	*	*	*			√		*	Antidiabetic
Desvenlafaxine	*								Antidepressant
Dexmethylphenidate HCl									ADHD
Diffunisal	√			√					NSAID
Dipyridamole	√	√			√		√		Antiplatelet
Doxazosin Mesylate	√	√	√		√		√		Antihypertensive
Drotaverine HCl			√	√			√		Antispasmodic
Entacapone	√	√		√	√	√	√		Anti-Parkinson
Fenoprofen	√								NSAID
Flurbiprofen		√				√	√		NSAID
Fluvoxamine Maleate	√	√		√			√	*	Antidepressant
Glycopyrrolate	√					√			Anticholinergic Agent
Hydralazine HCl	√			*					Antihypertensive
Hydroxyzine Pamoate	*								Antihistamine
Irinotecan HCl Trihydrate	*	√							Oncology
Isosulfan Blue	√								Diagnostic Dye
L-Carglumic Acid	√								Ammonia Detoxicants
Lamotrigine	*	√		√	√	√	√	√	Antiepileptic
Levodropropizine		√				√			Antitussive, Cough suppressant
Levomepromazine Maleate		√	√						Antipsychotic
Lercanidipine		*							Antihypertensive
Lisdexamfetamine dimesylate	*							*	ADHD
Lurasidone HCl	*								Antipsychotic

√ Available / Approved

* Filed / Awaiting Approval

** To be Filed

Active Pharma Ingredients - Commercial

Product	USDMF	CEP	EDMF	C-DMF	CA-DIF	KDMF	RUSSIA	ANVISA BRAZIL	Therapeutic Use
Malathion									Cholinesterase Inhibitors
Maraviroc	√								Antiarrhythmic
Mebeverine HCl		√	√	√			√	√	Antispasmodic
Methylene Blue									Oxidation- Reduction Agent
Methylphenidate HCl		√		√	*			√	ADHD
Metyrosine	√				*				Catecholamine Synthesis Inhibitor
Midazolam	√	√	√		√	√	√	√	Anesthetic
Nitazoxanide	√								Anti-Infective
Oxolamine Citrate									Cough suppressant
Oxolamine Phosphate									Cough suppressant
Oxymetazoline		*							Decongestant, Vasoconstrictor
Pinavarium bromide	**								Antispasmodic
Pirfenidone	√	√		√	√	√			AntiInflammatory, Antifibrotic
Posaconazole	√								Antifungal
Probenecid	√								Uricosuric Agents
Pyridosigmine	*	*							Cholenesterase inhibitor
Quetiapine Fumarate	√	√		√	√	√	√	√	Antipsychotic
Ractopamine HCl	*				√			*	Animal Feed Additive
Rivaroxaban	√	√	√	√	√	√	√	*	Anticoagulant
Sulfasalazine	*								Anti-Inflammatory
Tamsulosin HCl	√	√		√	√	√	√	√	Benign Prostatic Hyperplasia
Tapentadol Phosphate			*						Analgesic
Tapentadol HCl		*							Analgesic
Trientine	√								Copper Chelating Agent
Trimebutine		*				√			Antispasmodic
Trimetazidine dihydrochloride		*						**	Antianginal
Venlafaxine HCl	*	√		*	*				Antidepressant
Zilpaterol									Veterinary
Zonisamide	*		√	√		√			Anticonvulsant

√ Available / Approved * Filed / Awaiting Approval ** To be Filed

Disclaimer: All transactions are carried out in accordance with the patent laws applicable in the user's country. Responsibility for third-party patent rights in a specific country lies exclusively with the buyer. The therapeutic uses listed for each product are indicative only and are not intended to advertise Cohance/ZCL/Avra products. Patented products are available for R&D use as permitted under 35 USC 271(e)(1).

Active Pharma Ingredients - Under Development

Product	Therapeutic Use	Development Status
Apixaban	Anticoagulant	Under Validation
Acotiamide	Anti-Dyspepsia	Under Validation
Dexlansoprazole	Proton Pump Inhibitors	Lab Validation
Edoxaban	Anticoagulant	Under Validation
Erdosteine	Mucolytic Agent	Under Validation
Hydroxyzine Pamoate	Antihistamine	Validation Completed
Indapamide	Antihypertensive	Under Validation
Lercanidipine	Antidepressant, Anxiolytic	Validation Completed
Loxoprofen	Non-Steroidal Anti-Inflammatory	Validation Completed
Nintedanib Esylate	AntiInflammatory, Antifibrotic	Lab Validation
Propafenone	Antiarrhythmic agents	Validation Completed
Pyridostigmine Bromide	Cholinesterase inhibitor	Validation Completed
Remimazolam Besylate (Intermediate)	Sedative, General Anesthetic	Validation Completed
Safinamide	Anti-Parkinson	Under Validation



Intermediates			
Product	Plant Validation	Current Status	CAS No.
3 -Amino-Piperidine-2,6-Dione HCl	Lenalidomide	Commercial	24666-56-6
3-Nitro-2- Bromomethyl Methyl Benzoate	Lenalidomide	Commercial	98475-07-1
2'-Amino-5'-hydroxypropiophenone (AHP)	Irinotecan	Commercial	35364-15-9
N-(4-(methylamino)benzoyl)-L-glutamic acid diethyl ester	Methotrexate	Commercial	2378-95-2

Intermediates		
Product	CAS No.	API
Phenyl-(2-pyridyl) acetamide	7251-52-7	Methylphenidate
Phenyl-2-(2'-piperidyl) acetamide	19395-39-2	Methylphenidate
threo-phenyl-2-piperidyl acetamide	50288-62-5	Methylphenidate
dl-threo-Ritalinic acid	54631-24-2	Methylphenidate
(2R)-phenyl[(2R)-piperidin-2-yl]ethanoic acid hydrochloride	741705-70-4	Dexmethylphenidate
(S)-tert-butyl 3-(tert-butoxy)-2-(nicotinamido)propanoate (R)-chloromethyl 2-((R)-2-methoxy-2-oxo-1-phenylethyl)piperidine-1-carboxylate	2229891-12-5 2229891-13-6	Serdexmethylphenidate
Tert-butyl N-[(2S)-6-[(2-methylpropan-2-yl)oxycarbonylamino]-1-oxo-1-[(2S)-1-phenylpropan-2-yl]amino]hexan-2-yl]carbamate (Lisdexamfetamine Intermediate (LDX)-I)	819871-13-1	Lisdexamfetamine dimesylate
2-aminomethyl-7-chloro-2,3-dihydro-5-(2-fluorophenyl)-1H-1,4-benzodiazepine dimaleate	59469-29-3	Midazolam
2-[(2S)-oxiran-2-ylmethyl]-1H-isoindole-1,3(2H)-dione	161596-47-0	Rivaroxaban
5-chlorothiophene-2-carboxylic acid	24065-33-6	Rivaroxaban
(2S, 3R)-1-(Dimethylamino)-3-(3-methoxyphenyl)-2-methyl-3-pentanol	809282-20-0	Tapentadol
3-Methoxy propiophenone	37951-49-8	Tapentadol
3-Hydroxy propiophenone	13103-80-5	Tapentadol
2-(2,3-Dichlorophenyl)-2-(guanidinylimino)acetonitrile (Schiff Base)	84689-20-3	Lamotrigine
Methyl Olivetolate	58016-28-7	Cannabidiol
Olivetol	500-66-3	Cannabidiol
Menthadienol (MTH)	22972-51-6	Cannabidiol
4-Amino-2-chloro-6,7-dimethoxyquinazoline	23680-84-4	Doxazosin Mesylate
Methyl 3-((3S)-7-bromo-2-((2-hydroxypropyl)amino)-5-(pyridin-2-yl)-3H-benzo[e][1,4] diazepin-3-yl)propanoate (REM-II)	308243-54-1	Remimazolam Besylate
(S)-2-((S)-4-methyl-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamido)-3-phenylpropanoic acid	868540-16-3	Carfilzomib
(S)-2-amino-4-methyl-1-((R)-2-methoxypropan-2-yl)pentan-1-one trifluoroacetic acid salt	247068-85-5	Carfilzomib
(5-Bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone	461432-22-4	Dapagliflozin and Ertugliflozin
5-Bromo-2-chloro-4'-ethoxydiphenylmethane	461432-23-5	Dapagliflozin and Ertugliflozin
(S)-8-Ethyl-8-hydroxy-2,3,5,8-tetrahydro-6-oxa-3a-aza-cyclopenta [b] naphthalene-1,4,7-trione	110351-94-5	Irinotecan
2'-Amino-5'-hydroxypropiophenone	35364-15-9	Irinotecan
7-Ethyl-10-hydroxycamptothecin (SN-38)	86639-52-3	Irinotecan
10-Hydroxycamptothecin	19685-09-07	Topotecan
4-Fluoro-2-methoxy-5-nitroaniline	1075705-01-9	Osimertinib
N-(4-Fluoro-2-methoxy-5-nitrophenyl)-4-(1-methyl-1H-indol-3-yl)-2-pyrimidinamine	1421372-94-2	Osimertinib

Preformulation Intermediates (Pellets)										
Product	DMF/ Tech Pack	Bioequivalence Established	Type of BE Study	RLD/ Market	Stability	Brazil	Turkey	Mexico	MENA	APAC
Duloxetine HCl Delayed Release Pellets 20% (HPMC Acetyl Succinate)	DMF	Yes	Fast & Fed	CYMBALTA / EU	Available -36 M	Yes	Yes	Yes	Yes	Yes
Duloxetine HCl Delayed Release Pellets 20% (HPMC Phthalate)	DMF/ Tech Pack	Yes	Fasting & Fed	CYMBALTA/ Turkey/EU	Available -36 M	No	No	No	No	Yes
Duloxetine Delayed Release Pellets 17% (HPMC Phthalate)	DMF/ Tech Pack	No	No	-	Available - 12 M	Yes	No	No	Yes	Yes
Itraconazole Immediate Release Pellets 21.74%	DMF	Yes	Fasting & Fed	SPORANOX/ US	Available -36 M	No	No	Yes	No	Yes
Itraconazole Immediate Release Pellets 22%	DMF	No	No	-	Available -36 M	Yes	No	Yes	Yes	Yes
Venlafaxine HCl Extended Release Pellets 33%	Dossier/ DMF	Yes	Fasting & Fed	EFFEXOR /EU	Available -36 M	Yes	Yes	Yes	Yes	Yes
Omeprazole Delayed Release Pellets 8.5% (LD-30)	Dossier/ DMF	No		No	Available -36 M	No	No	Yes	Yes	Yes
Omeprazole Delayed Release Pellets 8.5% (Phthalate)	Dossier/ DMF	Yes	Fast & Fed	Customer Established BE in Indonesia	Available -36 M	No	No	Yes	Yes	Yes
Tamsulosin Modified Release Pellets 0.12%	Dossier	Yes	Fasting & Fed	FLOMAX/US, SANDOZ/ CANADA	Available - 6 M	No	No	No	Yes	No
Tamsulosin HCl Modified Release Pellets 0.2%	DMF	No	No	FLOMAX/US	Available -36 M	Yes	Yes	Yes	Yes	Yes
Mebeverine HCl Sustained Release Pellets 80%	DMF	Yes	Fast & Fed & MDD/ SS	Colofac Retard 200 mg/EU	Available -36 M	Yes	Yes	No	Yes	Yes
Fenofibrate Sustained Release Pellets 75%	DMF	No	No	No	Available -36 M	Yes	No	No	Yes	No
Orlistat Immediate Release Pellets 50% (Extrudes)	DMF	No	No	Xenical / EU	Available -36 M	Yes	No	Yes	Yes	Yes
Lansoprazole Delayed Release Pellets 8.5%	DMF	Yes	Fast & Fed	AGOPTON/ EU	Available -36 M	Yes	Yes	Yes	Yes	Yes
Methylphenidate HCl Extended Release Pellets 11%	DMF/ Tech Pack	Yes	Fast & Fed	RITALIN LA/ BR	Available -12 M	Yes	No	No	No	No
Methylphenidate HCl Immediate Release Pellets 11%	DMF/ Tech Pack	Yes	Fast & Fed	RITALIN LA/ BR	Available -12 M	Yes	No	No	No	No

Preformulation Intermediates - Under Development

Under development	DMF/ Tech Pack	Bioequivalence Established	Type of BE Study	RLD/ Market	Stability	Brazil	Turkey	Mexico	MENA	APAC
Duloxetine Hydrochloride Delayed Release Pellets 17%	Tech Pack	No	No	No	6M data available	-	-	-	-	-
Trimetazidine Extended Release Pellets 55%	Tech Pack	No	No	VASTAREL MR/ Brazil	6M data available	Yes	-	-	-	-
Dabigatran Etxilate Pellets 35%	Tech Pack	No	Fast Single Dose Study	PRADAXA/ US	3M data available	-	-	-	Yes	-





Cohance

Collaborate.
Enhance.
Deliver.

cohance.com